We are live on ! Find out more
ALLR

Allarity Therapeutics
ALLR

9 hedge funds and large institutions have $86.5K invested in Allarity Therapeutics in 2025 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

50% more funds holding

Funds holding: 6 → 9 (+3)

0.27% less ownership

Funds ownership: 2.36% → 2.08% (-0.27%)

29% less capital invested

Capital invested by funds: $122K → $86.5K (-$35.7K)

Holders
9
Holders Change
+3
Holders Change %
+50%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
2
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$35.1K
2
Morgan Stanley
Morgan Stanley
New York
+$24.1K
3
CCM
Corsair Capital Management
New York
+$20.7K
4
Barclays
Barclays
United Kingdom
+$10.4K
5
TRCT
Tower Research Capital (TRC)
New York
+$454

Top Sellers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
-$78.7K
2
Goldman Sachs
Goldman Sachs
New York
-$24.1K
3
Citigroup
Citigroup
New York
-$14.4K

ALLR Hedge Fund Activity: Q1 2025 in Review

9 of the 7,476 institutional investors tracked by Wall St. Rank reported a position in Allarity Therapeutics (ALLR) for Q1 2025, worth a combined $86.5K — down 29% from $122K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new ALLR positions and 3 closed out — a net gain of 3 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Geode Capital Management, opening a new position worth an estimated $35.1K. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $78.7K sold.

  • 9 institutional investors held Allarity Therapeutics (ALLR) as of Q1 2025, up from 6 in Q4 2024.
  • Funds reported $86.5K of Allarity Therapeutics stock for Q1 2025, down 29% quarter-over-quarter.
  • 6 funds opened new Allarity Therapeutics positions in Q1 2025 and 3 closed out, a net change of +3 holders.
  • The largest Allarity Therapeutics buyer in Q1 2025 was Geode Capital Management, an estimated $35.1K added.
  • The largest Allarity Therapeutics seller in Q1 2025 was Stonepine Capital Management, an estimated $78.7K sold.

Based on aggregated 13F filings for Q1 2025.